[ Home ] [ Controlled Substances ] [ Opioids ]
NICOMORPHINE
|

https://loinc.org/loinc/4348-9/
Duration: Opioid agonist that is 2-3x the potency of Morphine. Is used in few countries. Rapid onset of effects, due to the increased lipid solubility. | |||
Route | Onset | Duration | After Effects |
---|---|---|---|
Tripsit Factsheets | |||
![]() Nicomorphine Basic Information: http://drugs.tripsit.me/nicomorphine | |||
Oral: | 15-30 minutes | 4-6 hours | 1-6 hours |
Intravenously: | 1-2 minutes | 2-4 hours | 1-6 hours |
![]() | |||
Avoid: All other CNS depressants. | |||
Rapid onset of effects, due to the increased lipid solubility. |
Doses:
Nicomorphine hydrochloride is an opioid analgesic used in the treatment of moderate to severe pain. It is given in oral doses of 5 to 10 mg daily or by intramuscular, slow intravenous, or subcutaneous injection in doses of 10 to 20 mg; higher doses have also been used. It may also be given rectally in usual doses of 10 to 20 mg daily.

https://drugster.org/analgesics-anti-inflammatory-drugs-and-antipyretics/nicomorphine-hydrochloride
Nicomorphine was first synthesized in 1904 and was patented as Vilan by Lannacher Heilmittel G.m.b.H. of Austria in 1957. It is used, particularly in the German-speaking countries and elsewhere in Central Europe and some other countries in Europe and the former USSR in particular, for post-operative, cancer, chronic non-malignant and other neuropathic pain. It is commonly used in patient-controlled analgesia (PCA) units. Nicomorphine's side effects are similar to those of other opioids and include itching, nausea and respiratory depression. It is considered by doctors to be one of the better analgesics for the comprehensive mitigation of suffering, as opposed to purely clouding the noxious pain stimulus, in the alleviation of chronic pain conditions. Nicomorphine is regulated in much the same fashion as morphine worldwide but is a Schedule I controlled substance in the United States and was never introduced there. Nicomorphine may appear on rare occasions on the European black market and other channels for unsupervised opioid users. It can be produced as part of a mixture of salts and derivatives of morphine by end users by means of treating morphine with nicotinic anhydride or related chemicals in an analogue of the heroin homebake process.
WADA adds ADHD drug to prohibited substances - theScore.com - Nicomorphine, an opioid analgesic drug available in parts of Europe and which is converted to morphine following administration, was added to the list of banned narcotics. Friday September 30, 2016 - thescore.com WADA releases list of prohibited substances - The Financial Express - Nicomorphine, an opioid analgesic drug available in parts of Europe and which is converted to morphine following administration, was added to the list of banned narcotics. WADA releases list of prohibited substances - Gulf News - Nicomorphine, an opioid analgesic drug available in parts of Europe and which is converted to morphine following administration, was added to the list of banned narcotics. WADA releases list of prohibited substances - Sports Illustrated - Nicomorphine, an opioid analgesic drug available in parts of Europe and which is converted to morphine following administration, was added to the list of banned narcotics. Clarifications on use of asthma drugs among changes to WADA Prohibited ... - Lisdexamfetamine, a drug used for treating attention deficit hyperactivity (ADHD) disorder and eating disorders, is also added to the banned stimulants list. Opioid analgesic nicomorphine is a new ... WADA publishes 2017 Prohibited List - UEFA.com - The World Anti-Doping Agency has published its 2017 Prohibited List, which will come into force on 1 January 2017. Players, team doctors and officials should note changes. WADA releases list of prohibited substances - ESPN - The World Anti-Doping Agency has released its 2017 list of prohibited substances for athletes, adding a drug used for treating attention deficit hyperactivity disorder and eating disorders.
| ||
Opioids | Link to this page |